NCT01883505View on ClinicalTrials.gov

A Phase 2a Study Followed to Evaluate the Safety, Tolerability and Levodopa Pharmacokinetics in Levodopa-treated Parkinson's Disease Patients Receiving ND0612

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 6, 2014

Primary Completion Date

April 26, 2015

Study Completion Date

April 26, 2015

Conditions
Parkinson's Disease
Interventions
DRUG

Levodopa and carbidopa

Subcutaneous continuous administration

DRUG

Placebo

Subcutaneous continuous administration

Trial Locations (3)

Unknown

Hadassah Medical Center, Jerusalem

Rabin Medical Center, Petah Tikva

Tel Aviv Medical Center, Tel Aviv

Sponsors

Lead Sponsor

NeuroDerm Ltd.
All Listed Sponsors
lead

NeuroDerm Ltd.

INDUSTRY

NCT01883505 - A Phase 2a Study Followed to Evaluate the Safety, Tolerability and Levodopa Pharmacokinetics in Levodopa-treated Parkinson's Disease Patients Receiving ND0612 | Biotech Hunter | Biotech Hunter